Date: 2015-08-06
Type of information: Nomination
Compound:
Company: Epizyme (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On August 6, 2015, Epizyme announced that Robert Bazemore will succeed Robert Gould , Ph.D. as President and Chief Executive Officer of Epizyme , effective September 10, 2015 . Robert Bazemore will also join the Epizyme board of directors. Dr. Gould has served on the Epizyme board of directors since 2008 and as CEO for the past five-and-a-half years. Following the transition, he will continue to serve on the board and will serve as a consultant to the company. Prior to joining Epizyme , Rob Bazemore served as Chief Operations Officer of Synageva through its acquisition in July 2015 by Alexion for $8.4 billion . At Synageva, Rob was responsible for establishing the company\'s global commercial and medical organization to support the first product launch, as well as for leading the broader transition to a sustainable commercial enterprise. He was intimately involved in establishing strategy, interacting with shareholders, analysts and the board of directors, and he was closely involved in the sale transaction to Alexion. Prior to Synageva, Rob spent 12 years in various leadership roles at several Johnson & Johnson operating businesses including Ethicon , Janssen Biotech , Centocor Ortho Biotech and Centocor. He has extensive experience leading pipeline strategy, business development, new product planning and development, marketing, and broad global commercial strategy. Most notably for Epizyme , he served as President of Janssen Biotech , an immunology and oncology business with over $7 billion in revenues. At Janssen , Rob led the integration of the Ortho Biotech and Centocor businesses. He led the commercial partnership with Pharmacyclics , which successfully launched the novel hematological malignancy product IMBRUVICA®, and he was instrumental in the integration of Cougar Biotechnology, subsequently leading the successful launch of another novel oncology product Zytiga®. Previously, Rob spent 11 years at Merck in various marketing, medical affairs and field sales leadership roles.
Financial terms:
Latest news:
